Intelligence · Patents
Patents expiring in 2044
Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.
- Patents
- 1,766
Quick answer
1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11982673
Methods
granted -
US 11981760
Therapeutic hydrogels and contact lens for corneal melting
granted -
US 11981752
Tumor associated monocyte/macrophage binding peptide and methods of use thereof
granted -
US 11981897
Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
granted -
US 11981750
Antigenic tripeptides derived from Mycobacterium avium subsp. paratuberculosis s-type strains, derivatives and uses thereof
granted -
US 11981912
Adeno associated virus vectors for the treatment of hunter disease
granted -
US 11981739
Chimeric antigen receptor specific for interleukin-23 receptor
granted -
US 11981736
Antibodies specific to glycosylated PD-1 and methods of use thereof
granted -
US 11981730
Anti-CXCL13 antibodies and methods of using the same
granted -
US 11987600
Contraceptive use of triterpenoids
granted -
US 11986515
Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS)
granted -
US 11986533
Macromonomers and bottle brush polymers for delivery of biological agents
granted -
US 11987610
T-cell modulatory multimeric polypeptides and methods of use thereof
granted -
US 11986561
Wound dressings and applications thereof
granted -
US 11986517
Cancer vaccines targeting mesothelin and uses thereof
granted -
US 11986449
Levodopa dosing regimen
granted -
US 11986442
Inhibition of respiratory complex III by ligands that interact with a regulatory switch
granted -
US 11987590
Compounds that participate in cooperative binding and uses thereof
granted -
US 11987792
Compositions and methods for inhibiting expression of the LECT2 gene
granted -
US 11987821
Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
granted -
US 11987628
Methods and compositions for modulating CAR-T activity
granted -
US 11987548
Methods of making bempedoic acid and compositions of the same
granted -
US 11987586
Pyrrolo[1,2-c]imidazole derivatives as orexin type 2 receptor agonists
granted -
US 11986537
Muscle targeting complexes and uses thereof for treating dystrophinopathies
granted -
US 11986534
Treatment of anthrax with pegylated capsule-degrading enzyme
granted -
US 11986471
Compounds and methods of use
granted -
US 11986511
Use of a VEGF antagonist to treat angiogenic eye disorders
granted -
US 11986454
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11986455
Methods of providing solriamfetol therapy to subjects with impaired renal function
granted -
US 11986481
Method of synthesizing thyroid hormone analogs and polymorphs thereof
granted -
US 11986446
Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
granted -
AU 2022263543
Pharmaceutical compositions comprising sorbitan esters
granted -
US 2024166750
GLYCOENGINEERED Fc VARIANT POLYPEPTIDES WITH ENHANCED EFFECTOR FUNCTION
granted -
US 11992532
Hydrogels and methods of using the same
granted -
US 11992495
Enhancing GABA's ability to modulate immune responses
granted -
US 11993594
IRAK inhibitors and method for making and using
granted -
US 11993660
Chimeric polypeptides and methods of altering the membrane localization of the same
granted -
US 11993793
Polynucleotides encoding engineered meganucleases having specificity for recognition sequences in the dystrophin gene
granted -
US 11992480
Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
granted -
US 11992506
Stem cell derived pancreatic islet differentiation
granted -
US 11992555
Solid solution compositions and use in chronic inflammation
granted -
US 11993655
Anti-PD-L1 antibody and use thereof
granted -
US 11992528
Compositions and methods for conjugating activatable antibodies
granted -
US 11993573
Chromane-substituted, tetrahydroquinoline-substituted and thiochromane-substituted heteroarotinoids as anti-cancer agents
granted -
US 11993789
Pichinde virus reverse genetics systems and methods of use
granted -
US 11992472
Compositions and methods for enhancing the efficacy of contraceptive microbicides
granted -
US 11993640
Treating inflammatory lung disease
granted -
US 11993641
Methods for modulating an immune response
granted
Frequently asked questions
How many pharma patents expire in 2044?
1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.